| |
Our main pages on this subject:
| 1. | Merck Frosst Canada - Major Accomplishments Overview | | | Their work resulted in the launch of SINGULAIR® in Canada in 1998, a revolutionary once-a-day tablet for asthma for patients as young as six, and made the Merck Frosst Centre for Therapeutic Research a leader in leukotriene research. for the Merck Frosst Centre for Therapeutic Research include the discovery of the cardiovascular drug BLOCADREN® (timolol maleate tablets) (1974), the muscle relaxant FLEXERIL® (cyclobenzaprine hydrochloride) (1978) and TIMOPTIC® (timolol maleate ophthalmic solution) for glaucoma (1978). The Canadian site has also contributed significantly to the clinical development of FOSAMAX® (alendronate sodium) for osteoporosis, MAXALT® (rizatriptan benzoate) for migraine, AGGRASTAT® (tirofiban hydrochloride) for unstable angina, CRIXIVAN® (indinavir sulfate) for HIV / AIDS, COZAAR® Â § (losartan potassium) for hypertension and ZOCOR® (simvastatin) for lowering cholesterol. ® Registered Trademark of Merck & Co, Inc Used under license.... | | | | 2. | Merck Frosst Canada - Canadian Clinical Research | | | McMaster University in Hamilton has conducted a number of studies on FOSAMAX® (alendronate sodium) over the years.... | | | | 3. | Merck Frosst Canada - FOSAMAX® | | | Merck Frosst Canada - FOSAMAX®PrFOSAMAX® (alendronate sodium tablets) (alendronate sodium oral solution)Original Notice of Compliance (NoC). | | | | 4. | Merck Frosst Canada - FOSAVANCE® | | | PrFOSAVANCE® (alendronate sodium / cholecalciferol tablets)... | | | | 5. | Merck Frosst Canada - Company Press Releases | | | According to numerous studies, alendronate sodium has demonstrated consistent and substantial reductions in hip, , and spine fractures, ,, , as well as substantial increases in bone mineral density (BMD), the amount of calcium contained in bone, ,, and reductions in bone turnover (the rate at which bone is lost). ,... | | |
|
